6/30/2020 9:07:16 AM
Alnylam Presents New Data From Open-label Extension Period Of
ENVISION Phase 3 Study
5/26/2020 7:04:10 AM
Alnylam Says FDA Granted Priority Review Of Lumasiran NDA
5/6/2020 8:04:03 AM
Alnylam Pharma Q1 GAAP Loss Per Share $1.62; Non-GAAP Loss Per Share $1.52
5/4/2020 7:34:03 AM
Vir Biotechnology And Alnylam Identify VIR-2703 Targeting SARS-CoV-2 For Treatment Of COVID-19
4/14/2020 7:03:36 AM
Alnylam Says FDA Granted Fast Track Designation To Vutrisiran
4/13/2020 7:34:59 AM
Blackstone To Provide Up To $2 Bln To Support Alnylam's Advancement Of RNA Interference Medicines
4/7/2020 7:05:26 AM
Alnylam Pharma Submits Marketing Authorization Application To EMA For Lumasiran For Primary Hyperoxaluria Type 1
4/6/2020 7:08:39 AM
Alnylam, Dicerna Form Collaboration On Investigational RNAi Therapeutics For Treatment Of Alpha-1 Liver Disease
3/4/2020 7:04:06 AM
Vir, Alnylam Expand Collaboration To Advance RNAi Therapeutics For Coronavirus Infection, Incl COVID-19